<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> is characterised by retention of atherogenic particles, which are depleted of cholesterol </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, calculating or measuring <z:chebi fb="15" ids="39026">LDL</z:chebi> or <z:chebi fb="0" ids="47773">VLDL cholesterol</z:chebi> may not reflect the actual number of these atherogenic particles </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the potential role of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B in the risk stratification of Omani patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Two hundred and twenty-one subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and 67 healthy controls were recruited </plain></SENT>
<SENT sid="4" pm="."><plain>Diabetic subjects had significantly higher serum levels of <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (P&lt;0.0001), non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (P&lt;0.0001), and total/<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio (P&lt;0.04) and lower levels of <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (P&lt;0.0001) and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi>(a) compared to nondiabetic subjects </plain></SENT>
<SENT sid="5" pm="."><plain>The ratio of apoB/<z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> ratio was significantly higher (P&lt;0.002) among diabetic compared to nondiabetic subjects </plain></SENT>
<SENT sid="6" pm="."><plain>Sixty percent of the diabetic subjects with abnormal apoB of &gt;1.2g/L had an <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> of less than 4.2 mmol/L compared to 7% of the nondiabetic subjects (sensitivity; 40% versus 93%, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, diabetic subjects with <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischaemic heart disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e>) had significantly higher (P&lt;0.003) apoB/non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio compared to those without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that the ratios of apoB/<z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and apoB/non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> may have a role in the risk stratification of diabetic patients with <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
</text></document>